The Danish company becomes the latest large pharma company to invest in NLRP3 assets, with these types of treatments holding the potential to treat a variety of diseases linked to inflammation.
OSP’s list of the year’s most-read stories shows readers are interested in M&A activities, new drug candidates, COVID-19 developments, and other hot news.
The pharmaceutical company has announced GMP-related challenges with a manufacturer contracted to fill syringes for Wegovy pens headed to the US market.
The pharmacy company's Wegovy (semaglutide) is the first therapy designated for chronic weight management that the agency has granted approval since 2014.
The Orchestrated Customer Engagement Technology reportedly has been adopted by 140 life sciences companies (including top-10 pharma firms) in nearly 90 countries.
Novo Nordisk completes the construction of a wastewater treatment plant in Clayton, North Carolina, which will be donated to the city to aid biopharma growth.
Through funding by Novo Nordisk and the NIH, researchers from MIT have come up with a microneedle containing capsule able to release drug substance into the bloodstream.
As a day of climate strikes unfolds across the world, we ask how far pharma is engaged on the issue, as well as noting recent innovations that suggest companies are looking at what can be done.
Novo Nordisk and Roche/Genentech top this year’s Good Pharma Scorecard, which was, established to provide rankings of pharmaceutical companies’ clinical trial transparency and data sharing practices.
Although the industry may not be among the ‘frontrunners’, Novo Nordisk is seeing the benefits when it comes to recruitment and developing mutually beneficial partnerships, says director.
The Danish company is set to use only renewable electricity to run its global production facilities by 2020, after an investment of $70m in a 672-acre solar panel installation.
France, Germany, and the UK recently formed INSTEX to be able to secure trade despite US sanctions on Iran, a move that has been welcomed by Novo Nordisk.
Novartis joined industry associations in expressing concerns over the impact that a ‘hard’ or ‘disorderly’ Brexit could have on the life sciences sector.
Novo Nordisk Pharmatech selected DKSH to distribute its pharmaceutical grade compounds to the company’s growing customer base in the Asia-Pacific region.
The more outsourcing experience a pharma company has, the less important its proximity to contract manufacturing partners becomes, outlines Novo Nordisk VP.
TrialScope this year awarded several companies for their clinical trial data transparency efforts as the industry makes strides to engage patients and the larger health care community.
Novo Nordisk’s once-weekly diabetes treatment Ozempic has been given the US FDA green light, and the firm said it expects approval in Europe and Japan early 2018.
Dubbed LAB282, the £13m (€15M) Oxford University drug discovery program with Evotec has announced two grant winners and a second set of awards of up to £250,000.
Novo Nordisk could spend up to $2bn (€1.8bn) on two facilities to support its diabetes portfolio, including an oral long-acting GLP-1 analogue set to enter Phase III trials.
Novo Nordisk has confirmed it will build an API plant in the US, telling this publication a desire to have manufacturing capacity in the key market for its oral diabetes candidate, semaglutide, drove the decision.
Novo Nordisk has ended a development partnership using Zosana Pharma’s microneedle patch system with its GLP-1 analogue semaglutide, currently being investigated in an oral formulation.
Kaare Schultz, Novo Nordisk Chief Operating Officer and planned successor as Chief Executive, resigned unexpectedly today. Plus FDA's ex-top scientist heads up US Pharmacopoeia.
